Nutex Health, Inc. (NUTX)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$193.24-2.25%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
QuarterlyIQ Insights · NUTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -62.1% |
| Our one-year growth estimate | diamond | 10.4% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 72.5 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 26 industry peers · Company calendar date is not available
NUTX — earnings miss
Dated 2026-03-05
OF THIS CURRENT REPORT, INCLUDING EXHIBIT 99.1 ATTACHED HERETO, SHALL NOT BE DEEMED “FILED” FOR THE PURPOSES OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, NOR SHALL IT BE DEEMED INCORPORATED BY REFERENCE INTO ANY REGISTRATION STATEMENT OR OTHER FILING PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, EXCEPT AS OTHERWISE EXPRESSLY STATED IN SUCH FILING SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be si…
Why it matters: Stable revenue growth is important after recent drops. It shows recovery and success.
Watch forTotal revenue growth stabilizes or increases in Q3 2026.
Also watch forTotal revenue continues to decline year over year.
Why it matters: Lower arbitration costs can help make more money. It shows good management of expenses.
Supportive ifContract services expenses decrease by 25-30% in the second half of 2026.
Worry ifContract service costs do not go down as expected. They may even go up instead.
Why it matters: Meeting the EPS target shows strong earnings performance. It can boost investor confidence.
Supportive ifDiluted EPS for Q3 2026 is $15.87 or higher.
Worry ifDiluted EPS for Q3 2026 falls below $15.87.
Why it matters: Comparing Nutex to peers like Lilly and AbbVie can show if Nutex is gaining or losing ground. This helps investors understand its market position.
Watch forNutex's score is now above 21. This is better than its peers.
Also watch forNutex's composite insight score drops below 19, lagging peers.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$210 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $764 loss on $10,000 · 7.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,432 loss on $10,000 · 54.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: A drop below median growth in the health care sector could signal a broader slowdown. It may affect Nutex's growth outlook.
Worry ifSector revenue growth reported below its median.
Less concerning ifSector revenue growth remains above its median.
Why it matters: The success of IDR claims directly affects revenue. High success rates can boost financial performance.
Watch forIDR claims success rate remains above 85% with revenue growth.
Also watch forIDR claims success rate drops below 85% or revenue declines.
Why it matters: Earnings results will show how well Nutex is managing in a tough sector. Investors will gauge growth and profitability.
Watch forEarnings report shows revenue growth above 10% year over year.
Also watch forEarnings report shows revenue growth below 5% year over year.
Why it matters: Lower arbitration costs can help make more money. This change is important for future earnings.
Supportive ifContract service costs are down by 25-30% from past averages.
Worry ifContract services costs do not drop as expected or go up instead.
Why it matters: Revenue trends at current hospitals show how well they are doing. A drop could mean bigger problems.
Worry ifQ3 revenue at same hospitals declines worse than -6.0% year over year.
Less concerning ifRevenue at same hospitals stabilizes or grows year over year.
Why it matters: Achieving this EPS target reflects strong financial performance and growth. It impacts investor confidence.
Supportive ifDiluted EPS reported at $15.87 or higher for the full year 2026.
Worry ifDiluted EPS falls below $15.87 for the full year 2026.
Why it matters: Opening new hospitals is key to Nutex's growth strategy. Success here could boost revenues.
Supportive ifAll three new hospitals will open by the end of 2026.
Worry ifFailure to open any of the planned hospitals by the end of 2026.